Pedro Pagan Banchs
Pediatric Endocrinology · Miami, FLNPI 1760739957
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.0% of the total across 162 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 38 manufacturers, the largest accounting for just 19.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $974 and has fallen 74.4% since, to $249 in 2025.
Across 162 payments — averaging $22.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insulet Corporation$695
- AbbVie$357
- Novo Nordisk$206
- Tandem Diabetes Care, Inc.$185
- Eton Pharmaceuticals, Inc.$185
- Abbott$171
- plus $2K from 32 others
What the payments were for
- Food & beverage$3,49298%
- Education$732%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insulet Corporation | 21 | $695 |
| AbbVie | 21 | $357 |
| Novo Nordisk | 11 | $206 |
| Tandem Diabetes Care, Inc. | 10 | $185 |
| Eton Pharmaceuticals, Inc. | 2 | $185 |
| Abbott | 8 | $171 |
| AstraZeneca | 6 | $133 |
| BETA Bionics, Inc. | 7 | $133 |
| Sanofi-aventis U.S. LLC | 7 | $125 |
| Xeris Pharmaceuticals, Inc. | 7 | $124 |
| Ascendis Pharma Endocrinology Inc | 5 | $114 |
| Ipsen Biopharmaceuticals, Inc | 4 | $96 |
| Dexcom, Inc. | 4 | $73 |
| BD | 3 | $72 |
| Tolmar Pharmaceuticals, Inc. | 4 | $70 |
| Lifescan, Inc. | 4 | $70 |
| Arbor Pharmaceuticals, Inc. | 3 | $54 |
| Azurity Pharmaceuticals, Inc. | 3 | $53 |
| Lilly USA, LLC | 3 | $53 |
| Amneal Pharmaceuticals LLC | 3 | $50 |
| Biomarin Pharmaceutical Inc. | 2 | $45 |
| Ultragenyx Pharmaceutical Inc. | 2 | $44 |
| Kyowa Kirin, Inc. | 2 | $42 |
| Zealand Pharma US, Inc. | 2 | $41 |
| Endo Pharmaceuticals Inc. | 2 | $40 |
| Rhythm Pharmaceuticals, Inc. | 2 | $38 |
| Mannkind Corporation | 2 | $34 |
| Medtronic | 2 | $33 |
| Neurocrine Biosciences, Inc. | 1 | $30 |
| Amphastar Pharmaceuticals, Inc. | 1 | $25 |
| Dermira, Inc. | 1 | $25 |
| Nestle Healthcare Nutrition Inc. | 1 | $24 |
| Embecta Corp. | 1 | $24 |
| Recordati_rare_diseases_inc. | 1 | $23 |
| Companion Medical, Inc. | 1 | $21 |
| Endo USA, Inc. | 1 | $20 |
| Amryt Pharma Holdings Ltd | 1 | $18 |
| Chiesi USA, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,565 in reported general payments places this provider in the 65th percentile of 102 pediatric endocrinology providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GenotropinSomatropin | 11 | $22,164 |
Paid to pharmacies, not to this prescriber.
Other pediatric endocrinology in Miami
- Alejandro DiazMiami$101K
- Andrea GranadosMiami$19K
- Adriana Carrillo-IreguiMiami$19K
- Janine SanchezMiami$18K
- Joshua TarkoffMiami$9K
- Luis Gonzalez-MendozaMiami$9K
- Omar BeckettMiami$4K
- Carmen Bustamante EscobarMiami$3K
- Jonanlis Ramirez AlcantaraMiami$2K
- Marco DanonMiami$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.